Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Interviews with the Experts: Side Effects of PNH Treatment

    Although eculizumab (Soliris®) is known to be effective in treating PNH, it has ... The most frequently reported side effects of eculizumab in the PNH randomized trial were: headache, nasopharyngitis, back ... adverse reactions occurred among 4 (9%) patients receiving eculizumab and 9 (21%) patients receiving placebo (inactive ...

    Interview last updated 08/31/2016 - 8:37am.

  2. Thrombotic complications without evidence of hemolysis in paroxysmal nocturnal hemoglobinuria: is eculizumab indicated?

    Journal Title:  Ann Hematol Primary Author:  Bellido M Author(s):  Bellido M,...

    Research Article last updated 07/31/2012 - 12:44pm.

  3. Eculizumab treatment of paroxysmal nocturnal hemoglobinuria presenting as moyamoya syndrome in a 9-year-old male.

    Journal Title:  Pediatr Blood Cancer Primary Author:  Yen TA, Lu MY, Kuo MF, Huang CC, Chen JS, Yang YL ...

    Research Article last updated 04/24/2012 - 2:57pm.

  4. Hemolytic anemia after eculizumab in paroxysmal nocturnal hemoglobinuria.

    Journal Title:  N Engl J Med Primary Author:  Berzuini A Author(s):  Berzuini...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Paroxysmal nocturnal hemoglobinuria and eculizumab.

    Journal Title:  Haematologica Primary Author:  Luzzatto L Author(s):  Luzzatt...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria.

    Journal Title:  Am J Hematol Primary Author:  Emadi A Author(s):  Emadi A, Br...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Eculizumab

    ... Eculizumab causes the complement system , a part of your immune ...

    Drug last updated 03/24/2016 - 12:32pm.

  8. Fighting PNH with Perseverance and Spirit

    ... My hematologist and I agreed on the medication ( eculizumab , known as Soliris®) I should have. When I requested the ...

    Patient Chronicle last updated 04/26/2018 - 10:49am.

  9. Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab

    ... Eculizumab is indicated for the therapy of patients with symptomatic ... to inhibition of terminal complement cascade, patients on eculizumab are susceptible to Neisseria meningitidis infections. The two ...

    Research Article last updated 02/03/2017 - 11:21am.

  10. Eculizumab Protects Against TE and Prolongs Survival in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Study

    ... annual meeting in June focused on the effectiveness of eculizumab (Soliris®). Abstract EHA18ABSSUB-5522 Gerard Socie, ... hemoglobinuria (PNH). Clinical trials have shown that eculizumab (Soliris®) reduces rates of hemolysis , or the destruction ...

    Research Review last updated 05/02/2016 - 9:26am.